Screener
ADMA Biologics ADMA Deferred Revenue
Deferred Revenue at other companies
Other financials
Where this comes from
Reported directly by ADMA Biologics in its filing.
Tagged under the XBRL concept us-gaap:DeferredRevenueNoncurrent.
The source filing: ADMA Biologics’s 10-Q, filed August 5, 2026.
- Filed
- Aug 5, 2026, 5:16 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001140361-26-031445
| Line item | June 30, 2026 | December 31, 2025 |
|---|---|---|
| Liabilities held for sale | - | 2,647 |
| Total current liabilities | 75,757 | 69,541 |
| Long-term debt | 192,839 | 69,330 |
| Deferred revenue, net of current portion | 1,334 | 1,405 |
| Lease obligations, net of current portion | 6,072 | 6,646 |
| TOTAL LIABILITIES | 276,002 | 146,922 |
| COMMITMENTS AND CONTINGENCIES | ||
| STOCKHOLDERS' EQUITY |
Item 1. Financial Statements.
FAQ
- What is ADMA Biologics's deferred revenue?
- ADMA Biologics (ADMA) reported deferred revenue of $1.33M in Q2 2026.
- How has ADMA Biologics's deferred revenue changed year-over-year?
- ADMA Biologics's deferred revenue increased by 832.9% year-over-year, from $143K to $1.33M.
- What is the long-term trend for ADMA Biologics's deferred revenue?
- Over 5 years (2020 to 2025), ADMA Biologics's deferred revenue has grown at a 58.0% compound annual growth rate (CAGR), from $142.83K to $1.41M.
- What does deferred revenue mean?
- Payments received from customers for goods or services to be delivered within one year — recognized as revenue as performance obligations are satisfied.
Ask your AI about ADMA Biologics's deferred revenue.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude